Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Gabriel

Showing results (361-370 of 399) with videos related to

Pageof 40
Sort By:
American Heart Journal|August 30, 2024
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and designSneha S Jain, Kenneth W Mahaffey, Karen S Pieper, et al.
The New England Journal of Medicine|November 18, 2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stentsLaura Mauri, Dean J Kereiakes, Robert W Yeh, et al.
Journal of the American College of Cardiology|May 15, 2007
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trialDeepak L Bhatt, Marcus D Flather, Werner Hacke, et al.
The New England Journal of Medicine|May 4, 2012
Warfarin and aspirin in patients with heart failure and sinus rhythmShunichi Homma, John L P Thompson, Patrick M Pullicino, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 29, 2023
Impact of chronic kidney disease and diabetes on clinical outcomes in women undergoing PCIAlessandro Spirito, Dipti Itchhaporia, Samantha Sartori, et al.
American Heart Journal|September 20, 2005
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialDeepak L Bhatt, Keith A Fox, Werner Hacke, et al.
Journal of the American College of Cardiology|August 17, 2023
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary InterventionsGuiomar Mendieta, Shamir Mehta, Usman Baber, et al.
JAMA Cardiology|June 29, 2017
Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) CollaborationGennaro Giustino, Rafael Harari, Usman Baber, et al.
JACC. Cardiovascular Interventions|September 24, 2016
Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) CollaborationGennaro Giustino, Ioannis Mastoris, Usman Baber, et al.
JACC. Cardiovascular Interventions|October 25, 2023
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary InterventionDominick J Angiolillo, Davide Cao, Samantha Sartori, et al.
Pageof 40

Showing results (361-370 of 399) with videos related to

Sort By:
Pageof 40
American Heart Journal|August 30, 2024
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and designSneha S Jain, Kenneth W Mahaffey, Karen S Pieper, et al.
The New England Journal of Medicine|November 18, 2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stentsLaura Mauri, Dean J Kereiakes, Robert W Yeh, et al.
Journal of the American College of Cardiology|May 15, 2007
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trialDeepak L Bhatt, Marcus D Flather, Werner Hacke, et al.
The New England Journal of Medicine|May 4, 2012
Warfarin and aspirin in patients with heart failure and sinus rhythmShunichi Homma, John L P Thompson, Patrick M Pullicino, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 29, 2023
Impact of chronic kidney disease and diabetes on clinical outcomes in women undergoing PCIAlessandro Spirito, Dipti Itchhaporia, Samantha Sartori, et al.
American Heart Journal|September 20, 2005
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialDeepak L Bhatt, Keith A Fox, Werner Hacke, et al.
Journal of the American College of Cardiology|August 17, 2023
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary InterventionsGuiomar Mendieta, Shamir Mehta, Usman Baber, et al.
JAMA Cardiology|June 29, 2017
Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) CollaborationGennaro Giustino, Rafael Harari, Usman Baber, et al.
JACC. Cardiovascular Interventions|September 24, 2016
Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) CollaborationGennaro Giustino, Ioannis Mastoris, Usman Baber, et al.
JACC. Cardiovascular Interventions|October 25, 2023
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary InterventionDominick J Angiolillo, Davide Cao, Samantha Sartori, et al.
Pageof 40